Candida tropicalis has been identified as the most prevalent pathogenic yeast species of the Candida-non-albicans group. Historically, Candida albicans has been the major species responsible for causing candidiasis in immunocompromised and immunocompetent patients. However, infections (candidiasis) due to C. tropicalis have increased dramatically on a global scale thus proclaiming this organism to be an emerging pathogenic yeast. The reasons for this organism's dominance and its resistance to fluconazole have been difficult to elucidate. In addition, the mechanism of this organism's pathogenicity and the consequent immune response remain to be clarified. This paper describes certain predisposing factors potentially responsible for these characteristics and presents a ‘root cause analysis' to explain the increasing prevalence of C. tropicalis in developed and undeveloped countries, as well as the organism's acquired drug resistance. Control measures against fluconazole resistance in clinical management have also been discussed.
AntonopoulouS.,
AounM.,
AlexopoulosE. C.,
BakaS.,
LogothetisE.,
KalambokasT.,
ZannosA.,
PapadiasK.,
GrigoriouO.other authors2009; Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes. Antimicrob Agents Chemother 53:2181–2184[CrossRef]
BorgM.,
RüchelR.1990; Demonstration of fungal proteinase during phagocytosis of Candida albicans and Candida tropicalis
. J Med Vet Mycol 28:3–14[CrossRef]
Borg-von ZepelinM.,
BeggahS.,
BoggianK.,
SanglardD.,
MonodM.1998; The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages. Mol Microbiol 28:543–554[CrossRef]
BueschingW. J.,
KurekK.,
RobertsG. D.1979; Evaluation of the modified API 20C system for identification of clinically important yeasts. J Clin Microbiol 9:565–569
CapobiancoJ. O.,
LernerC. G.,
GoldmanR. C.1992; Application of a fluorogenic substrate in the assay of proteolytic activity and in the discovery of a potent inhibitor of Candida albicans aspartic proteinase. Anal Biochem 204:96–102[CrossRef]
DavisS. L.,
VazquezJ. A.,
McKinnonP. S.2007; Epidemiology, risk factors, and outcomes of Candida albicans versus non- albicans candidemia in nonneutropenic patients. Ann Pharmacother 41:568–573[CrossRef]
DixonT. C.,
SteinbachW. J.,
BenjaminD. K.Jr,
WilliamsL. W.,
MyersL. A.2004; Disseminated Candida tropicalis in a patient with chronic mucocutaneous candidiasis. South Med J 97:788–790[CrossRef]
GokceG.,
CerikciogluN.,
YagciA.2007; Acid proteinase, phospholipase, and biofilm production of Candida species isolated from blood cultures. Mycopathologia 164:265–269[CrossRef]
González-GravinaH.,
González-de MoránE.,
ZambranoO.,
Lozano-ChourioM.,
Rodríguez-de ValeroS.,
RobertisS.,
MesaL.2007; Oral Candidiasis in children and adolescents with cancer. Identification of Candida spp. Med Oral Patol Oral Cir Bucal 12:E419–E423
GruberA.,
LellC. P.,
SpruthM.,
Lass-FlörlC.,
SpethC.,
StoiberH.,
HubeB,
ColemanD,
PolonelliL.
other authors2003; HIV-1 and its transmembrane protein gp41 bind to different Candida species modulating adhesion. FEMS Immunol Med Microbiol 37:77–83[CrossRef]
HsuehP. R.,
LauY. J.,
ChuangY. C.,
WanJ. H.,
HuangW. K.,
ShyrJ. M.,
YanJ. J.,
YuK. W.,
WuJ. J.other authors2005; Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans , and Aspergillus species from Taiwan: Surveillance of Multicenter Antimicrobial Resistance in Taiwan program data from 2003. Antimicrob Agents Chemother 49:512–517[CrossRef]
HusainS.,
TollemarJ.,
DominguezE. A.,
BaumgartenK.,
HumarA.,
PatersonD. L.,
WagenerM. M.,
KusneS.,
SinghN.2003; Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 75:2023–2029[CrossRef]
ImamN.,
CarpenterC. C. J.,
MayerK. H.,
FisherA.,
SteinM.,
DanforthS. B.1990; Hierarchical pattern of mucosal Candida infections in HIV-seropositive women. Am J Med 89:142–146[CrossRef]
JacobsP. H.,
NallL.
(editors) 1990; Antifungal Drug Therapy: a Complete Guide for the Practitioner
. pp 32–45 New York: Marcel Dekker;
JorgeA. O. C.,
TottiM. A. G.,
de AlmeidaO. P.,
ScullyC.1993; Oral candidiasis established in the sialoadenectomised rat. J Oral Pathol Med 22:54–56[CrossRef]
KaoA. S.,
BrandtM. E.,
PruittW. R.,
ConnL. A.,
PerkinsB. A.,
StephensD. S.,
BaughmanW. S.,
ReingoldA. L.,
RothrockG. A.other authors1999; The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 29:1164–1170[CrossRef]
KhazimR. M.,
DebnathU. K.,
FaresY.2006; Candida albicans osteomyelitis of the spine: progressive clinical and radiological features and surgical management in three cases. Eur Spine J 15:1404–1410[CrossRef]
KirkpatrickC. H.,
RichR. R.,
BennettJ. E.1971; Chronic mucocutaneous candidiasis: model building in cellular immunity. Ann Intern Med 74:955–978[CrossRef]
KothariA.,
SagarV.2009; Epidemiology of Candida bloodstream infections in a tertiary care institute in India. Indian J Med Microbiol 27:171–172[CrossRef]
KothavadeR. J.,
PanthakiM. H.1998; Evaluation of phospholipase activity of Candida albicans and its correlation with pathogenicity in mice. J Med Microbiol 47:99–102[CrossRef]
KrasnerR. I.2002Concepts of microbial disease. In The Microbial Challenge: Human–Microbe Interactions , chapter 6 pp 103–120 Washington, DC: American Society for Microbiology;
NucciM.,
ColomboA.2007; Candidemia due to Candida tropicalis : clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals. Diagn Microbiol Infect Dis 58:77–82[CrossRef]
ParthibanC. J. K. B.,
MajeedS. A.,
MahalingamS. S.2008; Candida tropicalis spondylodiskitis in a patient with carcinoma of sigmoid colon: a case report. Cases J 1:66[CrossRef]
PfallerM. A.,
BoykenL.,
HollisR. J.,
KroegerJ.,
MesserS. A.,
TendolkarS.,
DiekemaD. J.ARTEMIS DISK Global Antifungal Surveillance Group2009; Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 65:27–34[CrossRef]
PrasadK. N.,
AgarwalT.,
DixitA. K.,
TiwariD. P.,
DholeT. N.,
AyyagariA.1999; Role of yeast as nosocomial pathogens and their susceptibilities to fluconazole and amphotericin B. Indian J Med Res 110:11–17
RhoadsJ. L.,
WrightD. C.,
RedfieldR. R.,
BurkeD. S.1987; Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA 257:3105–3107[CrossRef]
RoilidesE.,
FarmakiE.,
EvdoridouJ.,
FrancesconiA.,
KasaiM.,
FiliotiJ.,
TsivitanidouM.,
SofianouD.,
KremenopoulosG.,
WalshT. J.2003; Candida tropicalis in a neonatal intensive care unit: epidemiologic and molecular analysis of an outbreak of infection with an uncommon neonatal pathogen. J Clin Microbiol 41:735–741[CrossRef]
RüchelR.,
BöningB.,
BorgM.1986; Characterization of a secretory proteinase of Candida parapsilosis and evidence for the absence of the enzyme under conditions of infection in vitro. Infect Immun 53:411–419
SandfordG. R.,
MerzW. G.,
WingardJ. R.,
CharacheP.,
SaralR.1980; The value of fungal surveillance cultures as predictors of systemic fungal infections. J Infect Dis 142:503–509[CrossRef]
SanglardD.,
OddsF. C.2002; Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2:73–85[CrossRef]
ShirakiY.,
IshibashiY.,
HirumaM.,
NishikawaA.,
IkedaS.2008; Candida albicans abrogates the expression of interferon-gamma-inducible protein-10 in human keratinocytes. FEMS Immunol Med Microbiol 54:122–128[CrossRef]
SimJ. P.,
KhoB. C.,
LiuH. S.,
YungR.,
ChanJ. C.2005; Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin. Hong Kong Med J 11:120–123
StoneH. H.,
KolbL. D.,
CumeC. A.,
GeheberC. E.,
CuzzellJ. Z.1974; Candida sepsis: pathogenesis and principles of treatment. Ann Surg 179:697–711[CrossRef]
TortoranoA. M.,
RigoniA. L.,
BiraghiE.,
PrigitanoA.,
VivianiM. A.FIMUA-ECMM Candidemia Study Group2003; The European Confederation of Medical Mycology (ECMM) survey of candidemia in Italy: antifungal susceptibility patterns of 261 non- albicans Candida isolates from blood. J Antimicrob Chemother 52:679–682[CrossRef]
VermaA. K.,
PrasadK. N.,
SinghM.,
DixitA. K.,
AyyagariA.2003; Candidaemia in patients of a tertiary health care hospital from north India. Indian J Med Res 117:122–128
WalshT. J.,
MerzW. G.1986; Pathologic features in the human alimentary tract associated with invasiveness of Candida tropicalis
. Am J Clin Pathol 85:498–502
WeinbergerM.,
SacksT.,
SulkesJ.,
ShapiroM.,
PolacheckI.1997; Increasing fungal isolation from clinical specimens: experience in a university hospital over a decade. J Hosp Infect 35:185–195
WingardJ. R.,
DickJ. D.,
MerzW. G.,
SandfordG. R.,
SaralR.,
BurnsW. H.1980; Pathogenicity of Candida tropicalis and Candida albicans after gastrointestinal inoculation in mice. Infect Immun 29:808–813
WinstonD. J.,
PakrasiA.,
BusuttilR. W.1999; Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 131:729–737
YangY. L.,
HoY. A.,
ChengH. H.,
HoM.,
LoH. J.2004; Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis
. Infect Control Hosp Epidemiol 25:60–64[CrossRef]